Business
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
Presentations to highlight how GeneDx is leveraging AI to drive both better patient care and scale GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS),
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\nPresentations to highlight how GeneDx is leveraging AI to drive both better patient care and scale\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. GeneDx will showcase its leadership in genomic research and innovation, driving the industry forward with three platform presentations and two poster presentations.\n\nGeneDx earned one of the limited spots available for an industry-specific platform presentation on its AI-powered gene ranker embedded in its interpretation platform to enhance the speed and efficiency of clinical analysis. Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes with positive findings in exome and genome sequences by ranking them based on alignment with a patient’s clinical presentation. GeneDx’s AI-powered gene ranker accelerates analysis, reducing turnaround times and costs for patients and ultimately increasing access to care.\n\n\nMultiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes will be presented by Vinnie Ustach, PhD (GeneDx) on Thursday, March 20, 2025 at 12:00 pm PT in Meeting Room: Petree Hall D\n\n\nFeatured as a Top 20 Poster, GeneDx will also present findings from an RNA sequencing program used to aid in variant of uncertain significance (VUS) resolution for patients that received exome-based testing for rare disease.\n\n\nClinical Impact of RNA Sequencing on VUS Resolution in a Diverse Rare Disease Cohort of Over 100,000 Patients will be presented by Melanie Napier, MSc, MSc, CGC, CCGC (GeneDx) on Thursday, March 20 at 12:00 pm PT in the Exhibit Hall Learning Lounge and Friday, March 21 at 10:30 am PT at West Exhibit Hall A\n\n\n“GeneDx’s research, collaborations and AI-powered innovations being presented at ACMG reflect our commitment to advancing the utilization of exome and genome testing to improve patient care,” said Dr. Paul Kruszka, MD, FACMG, Chief Medical Officer at GeneDx. “By investing in industry-changing research and harnessing cutting-edge t...